全文获取类型
收费全文 | 5665篇 |
免费 | 282篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 133篇 |
妇产科学 | 166篇 |
基础医学 | 775篇 |
口腔科学 | 63篇 |
临床医学 | 549篇 |
内科学 | 1378篇 |
皮肤病学 | 88篇 |
神经病学 | 752篇 |
特种医学 | 112篇 |
外科学 | 538篇 |
综合类 | 23篇 |
一般理论 | 2篇 |
预防医学 | 284篇 |
眼科学 | 62篇 |
药学 | 377篇 |
中国医学 | 15篇 |
肿瘤学 | 628篇 |
出版年
2023年 | 44篇 |
2022年 | 67篇 |
2021年 | 133篇 |
2020年 | 91篇 |
2019年 | 112篇 |
2018年 | 142篇 |
2017年 | 111篇 |
2016年 | 121篇 |
2015年 | 132篇 |
2014年 | 184篇 |
2013年 | 249篇 |
2012年 | 358篇 |
2011年 | 366篇 |
2010年 | 181篇 |
2009年 | 213篇 |
2008年 | 361篇 |
2007年 | 356篇 |
2006年 | 371篇 |
2005年 | 353篇 |
2004年 | 298篇 |
2003年 | 277篇 |
2002年 | 224篇 |
2001年 | 124篇 |
2000年 | 124篇 |
1999年 | 103篇 |
1998年 | 61篇 |
1997年 | 56篇 |
1996年 | 52篇 |
1995年 | 49篇 |
1994年 | 41篇 |
1993年 | 33篇 |
1992年 | 58篇 |
1991年 | 58篇 |
1990年 | 47篇 |
1989年 | 44篇 |
1988年 | 59篇 |
1987年 | 44篇 |
1986年 | 32篇 |
1985年 | 24篇 |
1984年 | 26篇 |
1983年 | 18篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1979年 | 28篇 |
1978年 | 15篇 |
1977年 | 10篇 |
1974年 | 11篇 |
1972年 | 8篇 |
1969年 | 14篇 |
1967年 | 7篇 |
排序方式: 共有5978条查询结果,搜索用时 15 毫秒
71.
Tiziana Comito Mauro Loi Ciro Franzese Elena Clerici Davide Franceschini Marco Badalamenti Maria Ausilia Teriaca Lorenza Rimassa Vittorio Pedicini Dario Poretti Luigi Alessandro Solbiati Guido Torzilli Roberto Ceriani Ana Lleo Alessio Aghemo Armando Santoro Marta Scorsetti 《Current oncology (Toronto, Ont.)》2022,29(11):8802
Background: Hepatocellular carcinoma (HCC) is the most frequent liver malignancy and a leading cause of cancer death in the world. In unresectable HCC patients, transcatheter arterial (chemo-) embolization (TAE/TACE) has shown a disease response in 15–55% of cases. Though multiple TAE/TACE courses can be administered in principle, Stereotactic Body Radiotherapy (SBRT) has emerged as an alternative option in the case of local relapse following multiple TAE/TACE courses. Methods: This is a single-center, prospective, randomized, controlled, parallel-group superiority trial of SBRT versus standard TAE/TACE for the curative treatment of the intermediate stage of HCC after an incomplete response following TAE/TACE (). The primary endpoint is 1-year local control (LC): 18 events were needed to assess a 45% difference (HR: 0.18) in favor of SBRT. The secondary endpoints are 1-year Progression-Free Survival (PFS), Distant Recurrence-Free Survival (DRFS), Overall Survival (OS) and the incidence of acute and late complications. Results: At the time of the final analysis, 40 patients were enrolled, 19 (49%) in the TAE/TACE arm and 21 (51%) in the SBRT arm. The trial was prematurely closed due to slow accrual. The 1- and 2-year LC rates were 57% and 36%. The use of SBRT resulted in superior LC as compared to TAE/TACE rechallenge (median not reached versus 8 months, p = 0.0002). PFS was 29% and 16% at 1 and 2 years, respectively. OS was 86% and 62% at 1 year and 2 years, respectively. In the TAE arm, PFS was 13% and 6% at 1 and 2 years, respectively. In the SBRT arm, at 1 and 2 years, PFS was 37% and 21%, respectively. OS at 1 and 2 years was 75% and 64% in the SBRT arm and 95% and 57% in the TACE arm, respectively. No grade >3 toxicity was recorded. Conclusions: SBRT is an effective treatment option in patients affected by inoperable HCC experiencing an incomplete response following ≥1 cycle of TAE/TAC. NCT02323360相似文献
72.
Dixon B. Kaufman George W. Burke III David S. Bruce Christopher P. Johnson A. Osama Gaber David E. R. Sutherland Robert M. Merion Scott A. Gruber Eugene Schweitzer John P. Leone Christopher L. Marsh Edward Alfrey Waldo Concepcion Mark D. Stegall James A. Schulak Paul F. Gores Enrico Benedetti Craig Smith Alice K. Henning Fernando Kuehnel Sarah King William E. Fitzsimmons 《American journal of transplantation》2003,3(7):855-864
A randomized, multicenter, prospective study was conducted at 18 pancreas transplant centers in the United States to determine the role of induction therapy in simultaneous pancreas-kidney (SPK) transplantation. One hundred and 74 recipients were enrolled: 87 recipients each in the induction and noninduction treatment arms. Maintenance immunosuppression consisted of tacrolimus, mycophenolate mofetil, and corticosteroids. There were no statistically significant differences between treatment groups for patient, kidney, and pancreas graft survival at 1-year. The 1-year cumulative incidence of any treated biopsy-confirmed or presumptive rejection episodes (kidney or pancreas) in the induction and noninduction treatment arms was 24.6% and 31.2% (p = 0.28), respectively. The 1-year cumulative incidence of biopsy-confirmed, treated, acute kidney allograft rejection in the induction and noninduction treatment arms was 13.1% and 23.0% (p = 0.08), respectively. Biopsy-confirmed kidney allograft rejection occurred later post-transplant and appeared to be less severe among recipients that received induction therapy. The highest rate of Cytomegalovirus (CMV) viremia/syndrome was observed in the subgroup of recipients who received T-cell depleting antibody induction and received organs from CMV serologically positive donors. Decisions regarding the routine use of induction therapy in SPK transplantation must take into consideration its differential effects on risk of rejection and infection. 相似文献
73.
L Filippi P Fiorini M Daniotti S Catarzi S Savelli C Fonda L Bartalena A Boldrini M Giampietri R Scaramuzzo P Papoff F Del Balzo A Spalice G la Marca S Malvagia ML Della Bona G Donzelli F Tinelli G Cioni T Pisano M Falchi R Guerrini 《BMC pediatrics》2012,12(1):144
ABSTRACT: BACKGROUND: Despite progresses in neonatal care, the mortality and the incidence of neuro-motor disability after perinatal asphyxia have failed to show substantial improvements. In countries with a high level of perinatal care, the incidence of asphyxia responsible for moderate or severe encephalopathy is still 2--3 per 1000 term newborns. Recent trials have demonstrated that moderate hypothermia, started within 6 hours after birth and protracted for 72 hours, can significantly improve survival and reduce neurologic impairment in neonates with hypoxic-ischemic encephalopathy. It is not currently known whether neuroprotective drugs can further improve the beneficial effects of hypothermia. Topiramate has been proven to reduce brain injury in animal models of neonatal hypoxic ischemic encephalopathy. However, the association of mild hypothermia and topiramate treatment has never been studied in human newborns. The objective of this research project is to evaluate, through a multicenter randomized controlled trial, whether the efficacy of moderate hypothermia can be increased by concomitant topiramate treatment. METHODS: Term newborns (gestational age >= 36 weeks and birth weight >= 1800 g) with precocious metabolic, clinical and electroencephalographic (EEG) signs of hypoxic-ischemic encephalopathy will be randomized, according to their EEG pattern, to receive topiramate added to standard treatment with moderate hypothermia or standard treatment alone. Topiramate will be administered at 10 mg/kg once a day for the first 3 days of life. Topiramate concentrations will be measured on serial dried blood spots. 64 participants will be recruited in the study. To evaluate the safety of topiramate administration, cardiac and respiratory parameters will be continuously monitored. Blood samplings will be performed to check renal, liver and metabolic balance. To evaluate the efficacy of topiramate, the neurologic outcome of enrolled newborns will be evaluated by serial neurologic and neuroradiologic examinations. Visual function will be evaluated by means of behavioural standardized tests. DISCUSSION: This pilot study will explore the possible therapeutic role of topiramate in combination with moderate hypothermia. Any favourable results of this research might open new perspectives about the reduction of cerebral damage in asphyxiated newborns. Trial registration Current Controlled Trials ISRCTN62175998; ClinicalTrials.gov Identifier NCT01241019; EudraCT Number 2010-018627-25. 相似文献
74.
75.
76.
Lynn Ang Kelley M. Kidwell Brendan Dillon Jacob Reiss Fang Fang Virginia Leone Kara Mizokami-Stout Rodica Pop-Busui 《Journal of diabetes and its complications》2021,35(8):107949
AimsSodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce blood pressure without compensatory heart rate elevation, possibly by modulating sympathetic/parasympathetic activity. This may contribute to their cardiovascular benefits in type 2 diabetes (T2D). We evaluated the effects of dapagliflozin (DAPA) on measures of cardiovascular autonomic neuropathy (CAN), cardiac function, and glucose variability (GV) in T2D.MethodsPilot, randomized, two-period crossover trial comparing 12-week DAPA versus 12-week glimepiride treatment on CAN measures (cardiovascular autonomic reflex tests and heart rate variability), B-type natriuretic peptide (BNP), and GV (Abbott's Libre Pro devices) using signed rank tests and mixed models from baseline to 12 weeks within and between each period.ResultsForty-five T2D participants on metformin monotherapy (mean age 57 ± 8 years, duration 7 ± 6 years, HbA1c 7.8 ± 1.3%) were enrolled with 41 completing the trial. There were no differences in CAN indices or BNP with each drug compared to baseline and each other. Participants on DAPA demonstrated greater weight loss, reduced time in hypoglycemia, and improved GV compared to glimepiride.ConclusionsShort term treatment with DAPA did not affect CAN measures or BNP in uncomplicated and relatively healthy T2D participants. Longer prospective studies in patients with advanced disease are needed to better understand relationships between SGLT-2 inhibitors and CAN.Clinical trial registration: NCT02973477 相似文献
77.
Andrea Vianello Claudio Semplicini Luciana Paladini Alessandra Concas Sabrina Ravaglia Serenella Servidei Antonio Toscano Tiziana Mongini Corrado Angelini Elena Pegoraro 《Lung》2013,191(5):537-544
Purpose
Type II glycogenosis (GSDII) is a rare and often fatal neuromuscular disorder caused by acid alpha-glucosidase deficiency. Although alglucosidase alfa enzyme replacement therapy (ERT) significantly improves outcomes in subjects with the infantile form, its efficacy in patients with the late-onset one is not entirely clear. The long-term efficacy of ERT in late-onset GSGII complicated by severe pulmonary impairment causing high mechanical ventilation dependency was investigated in this study.Methods
The long-term clinical efficacy of ERT was assessed in eight late-onset GSDII patients using home mechanical ventilation (HMV) by comparing their outcomes with those of six historical control patients (GSDII patients) who had received HMV alone. The number of hospitalizations due to pulmonary exacerbations and of hours of daily use of HMV were considered the study’s primary efficacy endpoints.Results
The treatment group showed an increased tendency toward shorter follow-up compared to the control group (35.8 ± 29.2 vs. 52.6 ± 8.55 months; p = 0.04). At the end of the study period, the daily use of HMV (12.5 ± 7.6 vs. 19 ± 14.3 h; p = 0.004) and the hospitalization rate [incidence rate ratio = 0.43 (95 % confidence interval 0.18–0.93); p = 0.03] were significantly lower in the patients receiving ERT. The differences in the forced vital capacity absolute value and percentage change from baseline were not significantly different in the two groups.Conclusions
ERT reduces ventilator dependency in late-onset GSDII patients and the need for hospitalization due to respiratory exacerbations. 相似文献78.
Antonio Leone Marzia Marino Claudia Dell’Atti Viola Zecchi Nicola Magarelli Cesare Colosimo 《Rheumatology international》2016,36(10):1335-1346
The ankylosed spine is prone to fracture even after minor trauma due to its changed biomechanical properties. The two central features of ankylosing spondylitis (AS) that promote the pathological remodeling of the spine are inflammation and new bone formation. AS is also associated with osteoporosis that is attributed to an uncoupling of the bone formation and bone resorption processes. Therefore, bone resorption occurs and promotes weakening of the spine as well as increased risk of vertebral fractures which can be hugely different in terms of clinical relevance. Even in the presence of symptomatic clinical vertebral fractures, the diagnosis can be overruled by attributing the pain to disease activity. Furthermore, given the highly abnormal structure of the spine, vertebral fracture diagnosis can be difficult on the basis of radiography alone. CT can show the fractures in detail. Magnetic resonance imaging is considered the method of choice for the imaging of spinal cord injuries, and a reasonable option for exclusion of occult fractures undetected by CT. Since it is equally important for radiologists and clinicians to have a common knowledge base rather than a compartmentalized view, the aim of this review article was to provide the required clinical knowledge that radiologists need to know and the relevant radiological semiotics that clinicians require in diagnosing clinically significant injury to the ankylosed spine. 相似文献
79.
80.
Role of dendritic cell-derived CXCL13 in the pathogenesis of Bartonella henselae B-rich granuloma 总被引:3,自引:0,他引:3 下载免费PDF全文